StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3029% below fair value
$25.13+0.09 (+0.36%)

Close on Nov 20, 2026Market cap $2.02BP/E 17.9Yield –

Veracyte net income

Net income is the profit left for shareholders after every expense, interest and tax.

Veracyte's net income for the twelve months ending Jun 30, 2026 was $114.48M, up 334.7% year over year. For fiscal 2025 it was $66.35M, up 174.9% from the year before. The highest annual figure on record is $66.35M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$66.35M+174.9%
FY2024Dec 31, 2024$24.14M–
FY2023Dec 31, 2023-$74.40M–
FY2022Dec 31, 2022-$36.56M–
FY2021Dec 31, 2021-$75.56M–
FY2020Dec 31, 2020-$34.91M–
FY2019Dec 31, 2019-$12.60M–
FY2018Dec 31, 2018-$23.00M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$25.49M–
Q1 FY2026Mar 31, 2026$28.71M+307.4%
Q4 FY2025Dec 31, 2025$41.15M+704.8%
Q3 FY2025Sep 30, 2025$19.14M+26.3%
Q2 FY2025Jun 30, 2025-$980.00K-117.1%
Q1 FY2025Mar 31, 2025$7.05M–
Q4 FY2024Dec 31, 2024$5.11M–
Q3 FY2024Sep 30, 2024$15.16M–
Q2 FY2024Jun 30, 2024$5.73M–
Q1 FY2024Mar 31, 2024-$1.86M–
Q4 FY2023Dec 31, 2023-$28.29M–
Q3 FY2023Sep 30, 2023-$29.62M–
Q2 FY2023Jun 30, 2023-$8.40M–
Q1 FY2023Mar 31, 2023-$8.09M–
Q4 FY2022Dec 31, 2022-$3.84M–
Q3 FY2022Sep 30, 2022-$8.72M–
Q2 FY2022Jun 30, 2022-$9.53M–
Q1 FY2022Mar 31, 2022-$14.46M–
Q4 FY2021Dec 31, 2021-$10.53M–
Q3 FY2021Sep 30, 2021-$14.13M–
Q2 FY2021Jun 30, 2021-$9.04M–
Q1 FY2021Mar 31, 2021-$41.87M–
Q4 FY2020Dec 31, 2020-$8.04M–
Q3 FY2020Sep 30, 2020-$4.12M–
Q2 FY2020Jun 30, 2020-$11.03M–
Q1 FY2020Mar 31, 2020-$11.72M–
Q4 FY2019Dec 31, 2019-$7.46M–
Q3 FY2019Sep 30, 2019-$730.00K–
Q2 FY2019Jun 30, 2019-$2.49M–
Q1 FY2019Mar 31, 2019-$1.92M–

More Veracyte figures

See a number that looks wrong?